Semaglutide
3 articles · search the full text for this term
-
GLP-1 Receptor Agonists: A Dual Therapeutic Strategy for the Management of Type 2 Diabetes Mellitus and Obesity
Abstract: For the treatment of obesity and type 2 diabetes mellitus (T2DM), glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become a revolutionary class of pharmaceutical drugs. These drugs were first created as glucose-lowering treatments, but they have now shown other advantages, such as notable weight loss, better cardiovascular results, and general metabolic control. The objective of this narrative review is to assess the pharmacological mechanisms, clinical efficacy, safety profile, and therapeutic …
Published in Research and Reviews: A Journal of Pharmacology · Vol. 16, Issue 1, 2026 · pp. 69–75 Read article
-
Evaluating the Role of Apple Cider Vinegar in Managing Semaglutide-Induced Gastrointestinal Disturbances: A Systematic Review
Abstract: Background: Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is highly effective in treating type 2 diabetes and obesity. However, its use is often associated with gastrointestinal side effects, including nausea, vomiting, and diarrhea, which may impact patient compliance. Objective: This systematic review aims to evaluate the evidence regarding the management of semaglutide-induced GI symptoms and assess the potential role of apple cider vinegar (ACV) as a complementary treatment. Methods: A …
Published in Research and Reviews: A Journal of Medicine · Vol. 15, Issue 1, 2025 · pp. 25–31 Read article
-
Assessing the Clinical Efficacy and Safety of Semaglutide: A Comprehensive Study
Abstract: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has emerged as a versatile therapeutic agent with significant potential in managing a range of diseases. Extensive research has demonstrated its efficacy in treating obesity, type 1 and type 2 diabetes, and even neurodegenerative disorders like Parkinson’s disease. This comprehensive review examines the principal outcomes derived from clinical trials that incorporate semaglutide alongside other GLP-1 agonists, with particular emphasis on the mechanisms underlying …
Published in Research and Reviews: A Journal of Pharmacology · Vol. 14, Issue 3, 2024 · pp. 96–104 Read article